NCT05112861 - A 3-month Study to Compare the Safety of ONS-5010 in Vials Versus Pre-filled Syringe in Subjects With Visual Impairment Due to Retinal Disorders | Biotech Hunter

Enrollment

120

Participants

Timeline

Start Date

November 15, 2021

Primary Completion Date

March 31, 2025

Study Completion Date

March 31, 2025

Conditions

Age-Related Macular DegenerationNeovascular Age-related Macular DegenerationWet Macular DegenerationBRVO - Branch Retinal Vein OcclusionDiabetic Macular Edema

Interventions

BIOLOGICAL

bevacizumab

1.25 mg, intravitreal injection

Trial Locations (3)

17201

Clinical Site, Chambersburg

21740

Clinical Site, Hagerstown

62704

Clinical Site, Springfield